Secondary hyperparathyroidism prevalence and profile, between diabetic and non-diabetic patients with stage 3 to 4 chronic kidney disease attended in internal medicine wards. MiPTH study
| Autor: | José Carlos Arévalo-Lorido, Juan Carlos Bureo-Dacal, Juana Carretero-Gómez, José Manuel Ramiro-Lozano, Francisco García-Sánchez, Nicolás Roberto Robles, Enrique Maciá-Botejara, Antonio Masero-Carretero |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
Vitamin medicine.medical_specialty Endocrinology Diabetes and Metabolism 030232 urology & nephrology 030209 endocrinology & metabolism Diabetes Complications 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Diabetes mellitus Internal Medicine medicine Humans Renal osteodystrophy Renal Insufficiency Chronic Risk factor Aged Dyslipidemias Aged 80 and over business.industry Hyperparathyroidism General Medicine medicine.disease Cross-Sectional Studies chemistry Parathyroid Hormone Spain Hypertension Multivariate Analysis Female Microalbuminuria Secondary hyperparathyroidism Hydroxymethylglutaryl-CoA Reductase Inhibitors business Dyslipidemia Glomerular Filtration Rate Kidney disease |
| Zdroj: | Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 10:S16-S21 |
| ISSN: | 1871-4021 |
| DOI: | 10.1016/j.dsx.2016.01.011 |
| Popis: | Aims Secondary hyperparathyroidism (SHPTH) is a leading cause of renal osteodystrophy, and an independent risk factor for all-cause and cardiovascular mortality. Our aim is to establish differences in prevalence and profile of SHPTH, regarding diabetics or non-diabetics with chronic kidney disease (CKD). Methods Cross-sectional multicenter study which included patients with stages 3 to 4 CKD. SHPTH was considered when the intact PTH levels (iPTH) were equal or higher than 70 pg/ml. We divided the sample into two groups (diabetics and non-diabetics). We used robust statistical methods. Results 409 patients (214 diabetics) were studied. HPTH was found in 60.4% of diabetics vs 65% of non-diabetics (P = 0.42). Diabetics with HPTH were younger (79.5 vs 82.3 years-old, P = 0.005), and had more hypertension (P = 0.0014), dyslipidemia (P = 0.0001) and comorbidities. In multivariate analysis, we found a significant relationship in case of diabetics, with age (OR: 1.04, 95%CI 1.005–1.09 P = 0.02 ), and with statins treatment (OR 2.3, 95%CI 1.17–4.54, P = 0.01). Discussion The prevalence of SHPTH between the groups was similar, however, diabetics had more presence of hypertension and dyslipidemia, and SHPTH in this case was also related with moderate microalbuminuria and lower levels of vitamin D. An association with statins was also found in this group. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect